Compass Therapeutics Inc (NASDAQ: CMPX) on Friday, plunged -14.52% from the previous trading day, before settling in for the closing price of $3.10. Within the past 52 weeks, CMPX’s price has moved between $0.76 and $3.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -6.06%. With a float of $83.22 million, this company’s outstanding shares have now reached $137.59 million.
The extent of productivity of a business whose workforce counts for 32 workers is very important to gauge. In terms of profitability, gross margin is 74.8%, operating margin of -1501.0%, and the pretax margin is -1292.88%.
Compass Therapeutics Inc (CMPX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Compass Therapeutics Inc is 39.51%, while institutional ownership is 43.47%.
Compass Therapeutics Inc (CMPX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -6.06% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.60% during the next five years compared to 12.88% growth over the previous five years of trading.
Compass Therapeutics Inc (NASDAQ: CMPX) Trading Performance Indicators
Compass Therapeutics Inc (CMPX) is currently performing well based on its current performance indicators. A quick ratio of 31.84 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 428.95.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.36, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.40 in one year’s time.
Technical Analysis of Compass Therapeutics Inc (CMPX)
The latest stats from [Compass Therapeutics Inc, CMPX] show that its last 5-days average volume of 1.57 million was inferior to 3.12 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 83.59%. Additionally, its Average True Range was 0.28.
During the past 100 days, Compass Therapeutics Inc’s (CMPX) raw stochastic average was set at 74.24%, which indicates a significant increase from 71.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 177.17% in the past 14 days, which was higher than the 103.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.72, while its 200-day Moving Average is $1.50. Now, the first resistance to watch is $3.00. This is followed by the second major resistance level at $3.36. The third major resistance level sits at $3.60. If the price goes on to break the first support level at $2.41, it is likely to go to the next support level at $2.17. Assuming the price breaks the second support level, the third support level stands at $1.82.
Compass Therapeutics Inc (NASDAQ: CMPX) Key Stats
Market capitalization of the company is 364.61 million based on 137,589K outstanding shares. Right now, sales total 0 K and income totals -42,490 K. The company made 850 K in profit during its latest quarter, and -13,080 K in sales during its previous quarter.
